NCT03605199View on ClinicalTrials.gov

Denosumab in Subjects With Giant Cell Rich Tumors of Bone

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 18, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2023

Conditions
Aneurysmal Bone CystsGiant Cell GranulomaOsteoblastomaChondroblastomaChondromyxoid Fibroma
Interventions
DRUG

Denosumab

Denosumab will be given in a dose of 120mg subcutaneously (SC) on day 1 of every 4 week cycle with a loading dose of 120mg SC on days 8 and 15 of the first cycle.

Trial Locations (3)

Unknown

NOT_YET_RECRUITING

Centre Léon Bérard, Lyon

NOT_YET_RECRUITING

Istituto Ortopedico Rizzoli, Bologna

RECRUITING

Leiden University Medical Center, Leiden

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Leiden University Medical Center

OTHER

NCT03605199 - Denosumab in Subjects With Giant Cell Rich Tumors of Bone | Biotech Hunter | Biotech Hunter